Management Team


Kent E. Pryor, PhD, MBA

Chief Executive Officer
  • Previously Chief Operating Officer of SynthRx; Associate Director of Drug Development at Kemia, and Group Leader at Corvas International
  • X01 grantee from NINDS for RHAPSODY Phase 2 study of 3K3A-APC in stroke patients

Howard Levy, MB BCh, PhD, MMM

Senior Medical Advisor
  • Previously CMO at Catalyst Biosciences; Sr. Global Medical Program Director at CSL Bering, SVP & CMO at Inspiration Biopharmaceuticals, and Chief of Critical Care Medicine , University of New Mexico
  • Former Clinical Research Physician and Medical Director, Acute Care, Eli Lilly and Company
  • Headed post-marketing clinical trials and medical affairs for recombinant Activated Protein C (Xigris) in severe sepsis

Susan Willingham

Director of Finance
• Senior Manager of the tax group, Pioneer Wealth Partners
• Formerly Senior Associate at the Quellos Group, providing wealth management services to high net worth families
• Certified Public Accountant

Craig Van De Mark, JD

VP, Legal
  • Legal expertise in Corporate Finance, M&A, Insurance & Risk Management and IP
  • Contracting including Licensing, Drug Manufacturing, Material Transfers and Clinical Trials
  • Previously General Counsel to Zilkha Biomass Energy and General Counsel to Zilkha Renewable Energy

Lisa Koch-Hulle, RAC

Head of Regulatory Affairs
  • Principal, LKH & Associates
  • Previously Vice President, Regulatory Affairs and Clinical Operations, La Jolla Pharmaceutical Company
  • Vice President, Clinical Operations and Regulatory Affairs for Light Sciences Oncology

Frieder Hofmann, PhD

Head of Quality
• Principal Consultant, ProCon International: Independent technical regulatory and process development consultant in mainly the recombinant protein and synthetic peptide areas since 1990
• Previously Technical Director of BioTechnetics, and Manager, Technical & Scientific Services for Brunswick GmbH

Scientific Advisory Board

Board of Directors